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Abstract 
Background: The focus of this study was to characterize a novel biomarker for cystic 
fibrosis (CF) that could reflect exacerbations of the disease and could be useful for 
therapeutic stratification of patients, or for testing of potential drug treatments. This study 
focused exclusively on a protein complex containing alpha-1 antitrypsin and CD16b 
(AAT:CD16b) which is released into the bloodstream from membranes of pro-
inflammatory primed neutrophils.   
Methods:  Neutrophil membrane expression and extracellular levels of AAT and CD16b 
were quantified by flow cytometry, Western blot analysis and by 2D-PAGE. Interleukin-
8 (IL-8), tumour necrosis factor-alpha (TNF-alpha) and AAT:CD16b complex were 
quantified in CF plasma (n=38), samples post antibiotic treatment for 14 days (n=10), 
chronic obstructive pulmonary disease (n=10), AAT deficient (n=10) and healthy control 
(n=14) plasma samples by ELISA.    
Results: Cell priming with IL-8 and TNF-alpha caused release of the AAT:CD16b 
complex from the neutrophil cell membrane. Circulating plasma levels of IL-8, TNF-
alpha and AAT:CD16b complex were significantly higher in patients with CF than in the 
other patient groups or healthy controls (P<0.05). Antibiotic treatment of pulmonary 
exacerbation in patients with CF led to decreased plasma protein concentrations of 
AAT:CD16b complex with a significant correlation with improved FEV1 (r= 0.84, 
P=0.005). 
Conclusion: The results of this study have shown that levels of AAT:CD16b complex 
present in plasma correlate to the inflammatory status of patients. The AAT:CD16b 
biomarker may become a useful addition to the clinical diagnosis of exacerbations in CF.  
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1. Introduction 
Cystic fibrosis is an autosomal recessive condition and although a multi-organ 
disorder, end-stage lung disease with chronic bacterial infection is the major cause of 
morbidity and mortality in affected individuals (1). The pathogenesis of lung disease 
induced by CF is a direct result of decreased chloride secretion and hyper-absorption of 
sodium, resulting in the retention of dehydrated mucus within the airways (2). This 
thickened mucus provides an ideal environment for bacterial infection in the respiratory 
tract. Staphylococcus aureus (S. aureus) is the major bacterial pathogen in early years but 
subsequently Pseudomonas aeruginosa (P. aeruginosa) becomes the prominent pathogen 
in adult patients (3, 4). Adding to this lung microbiome in CF, obligate anaerobes in CF 
sputum samples including Prevotella, S. saccharolyticus, Peptostreptococcus prevotii 
and Actinomyces have been detected (5, 6). Intravenous (i.v.) antibiotics are normally 
used for acute infective exacerbations with efficacy assessed by monitoring respiratory 
function, body weight and circulating markers of systemic inflammation (7).  
In addition to ineffective mucociliary and cough clearance, persistent expression 
of inflammatory cytokines and chemokines plays a major role in the pathogenesis of 
chronic lung disease (8), leading to recruitment and activation of neutrophils in the CF 
airways (9). Longitudinal and prospective studies of infants with CF and also within an 
animal model with mutated CFTR genes, demonstrates that airway inflammation follows 
respiratory infection (10). Thus an increasing volume of clinical data supports the use of 
early antimicrobial treatment to inhibit (11) or delay (12) bacterial infection and to 
achieve decreased hospitalization and improved patient survival. For this reason there has 
been increased interest in the use of infective exacerbations (frequency and resolution) as 
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an outcome measure in clinical trials and sensitivity to treatment. However, whilst there 
are a number of criteria put forward to define an exacerbation (13-16) variability among 
parameters exists (17). Moreover, as new agents are investigated in clinical trials and new 
therapeutic targets are identified, it is becoming increasingly important to accurately 
define the clinical signs and symptoms of pulmonary exacerbations and to define 
objective markers of infection (18). 
Inflammatory biomarkers represent a solution to the variation in the clinical 
criteria defining exacerbations in CF. Thus far identified biomarkers indicative of 
increased pulmonary inflammation with P. aeruginosa infection include serum levels of 
G-CSF (19) and matrix metalloproteinase-1, -8 and -9  (20). Alternatively levels of 
cytokines including IL-8 (21), neutrophil released elastase (22), myeloperoxidase (23) 
and cathepsin B and S (24) have been evaluated as markers of pulmonary exacerbation in 
sputum samples. However, one aspect of neutrophil physiology which has largely been 
overlooked is pre-activation or priming of the circulating cell. Neutrophil priming is a 
prerequisite for homing to the lung and can be used as read-out for the in vivo action of 
pro- and anti-inflammatory cytokines. Consequently, we hypothesized that markers of 
neutrophil priming in the systemic compartment would serve as an early read-out for 
pulmonary exacerbation in CF and should be normalized upon optimal treatment. 
Recently we have shown that the acute phase protein alpha-1 antitrypsin, is bound to the 
circulating neutrophil via interaction with the glycosylphosphatidyl-inositol (GPI) linked 
membrane protein CD16b (FcRIIIb) (25). Moreover, soluble immune complex (sIC) 
primed the circulating neutrophil to release AAT from the cell membrane within a protein 
complex with CD16b. Within the present study we investigated the potential of 
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neutrophil released AAT:CD16b protein complex to serve as a potential marker of 
infective inflammation and resolution of pulmonary exacerbation in adult patients with 
CF. Some of the results of this study have been previously reported in the form of an 
abstract (26). 
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2. Materials and methods 
2.1 Chemicals and reagents  
All chemicals and reagents were endotoxin free and were purchased from Sigma-
Aldrich unless indicated otherwise. 
 
2.2 Patient groups 
Four patient groups and healthy control volunteers were recruited to this study as 
follows: 1: Asymptomatic alpha-1 antitrypsin deficient individuals (AATD) not receiving 
therapy were recruited from the Irish Alpha-1 Antitrypsin Deficiency Registry (n=10, 
mean age 43.95 ± 8.53). AATD patients had plasma AAT levels  <11 M  and were 
clinically stable with a forced expiratory volume in one second (FEV1) of 98.2% ± 
17.48% predicted. 2: Adult patients with COPD (n=10) and a history of smoking were 
recruited as previously described (27).  3: Patients with CF (n=38, mean age 26.8 ± 5.9) 
were genotyped for cystic fibrosis transmembrane conductance regulator mutations. 
Treatment of an acute bacterial exacerbation in 10 patients with CF involved i.v. 
administration of colomycin (2 million units i.v. 3 times daily (t.d.s)), 
piperacillin/tazobactam (4.5g i.v. t.d.s.), flucloxacillin (2g i.v. 4 times daily (q.d.s)), 
meropenem (2g i.v. t.d.s.) and/or ciprofloxacin (400mg i.v. 2 times daily (b.d.)). An 
exacerbation was defined by previously validated criteria (28).  4: All non-CF 
bronchiectasis patients (n= 6, mean age 64 ± 6.7, mean % FEV1 of 59% predicted) were 
recruited from a specialized non-CF bronchiectasis clinic and had no evidence of an 
exacerbation at the time of recruitment. 5: Control volunteers (n=14, mean age 34.72 ± 
3.17) had no respiratory symptoms and were not on medication. All participants gave 
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written informed consent to participate in the study, which was approved by Beaumont 
Hospital Ethics Committee.    
 
2.3 Neutrophil isolation and membrane fractionation. 
Neutrophils were purified from whole blood and membranes were isolated as 
previously described employing sucrose density ultracentrifugation (25). The 
methodology for flow cytometry, proteomic analysis, SDS-PAGE and Western blotting 
of neutrophil plasma membranes can be found within the supplemental materials and 
methods.  
 
2.4 Enzyme linked immunosorbent assays (ELISAs) 
The concentration of IL-8 or TNF-alpha in plasma samples was measured by 
enzyme linked immunosorbent assay (ELISA), conducted in accordance
 
with the 
manufacturer’s instructions (R&D Systems). For the detection of AAT:CD16b complex 
within plasma samples of healthy control, AATD or patients with CF, 5g/ml of specific 
mouse anti-CD16b (R&D systems) was employed as a capture antibody and  50ng/ml of 
polyclonal goat anti-AAT specific antibody (Abcam) as a detection antibody, followed by 
an anti-goat IgG conjugated to HRP. Prior to each assay, wells from Nunc 96-well 
microtiter plates were coated with capture antibody suspended in Buffer A (15 mM 
Na2CO3 and 35 mM NaHCO3, pH 9.3) over night at 4°C. The wells were subsequently 
washed in Buffer A, blocked with bovine serum albumin (BSA; 1% w/v) for 1h and 
exposed to patient plasma (100l). As the ELISA was based on quantification of AAT 
complexed to CD16b that is captured by the anti-CD16b antibody, serial dilutions of 
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purified human AAT  was simultaneously coated in triplicate in the Nunc 96-well 
microtiter plate to establish a standard curve as previously described (29). Controls 
included all reagents except capture, detection antibody or biotinylated secondary 
antibody.   
 
2.5 Statistical analysis 
All experiments were performed a minimum of three times and results expressed 
as means ± standard error of the mean. The data was analyzed with the GraphPad Prism 
version 4.03 for Windows (GraphPad Software, USA). Continuous data were tested for 
normality (1 sample Kolmogorov - Smirnoff test) and where normal were compared 
using an unpaired student t-test. Differences were considered significant at P ≤ 0.05. 
Quantification of protein abundance was determined using the biological variation 
analysis module of Decyder™ using ANOVA-1 analysis for comparing across the 
different groups (healthy controls, non-CF bronchiectasis and CF samples pre- and post-
antibiotic treatment). Differential expression was defined as greater than 1.5-fold change 
in expression with a P-value ≤ 0.05.   
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3. Results  
3.1 Proinflammatory mediators cause release of AAT and CD16b from neutrophil 
membranes. 
We have previously shown that exposure of neutrophils to sIC causes release of 
AAT and CD16b from the neutrophil membrane in a complex form (25). To build on this 
background information the effect of the proinflammatory stimulus IL-8, on 
release/shedding of AAT and CD16b from the neutrophil membrane was investigated. 
Neutrophils were primed with IL-8 (10ng/2x10
7
 cells) and after 10 min of treatment a 
significant decrease in cell surface AAT was detected by flow cytometry (control 
untreated mean fluorescence = 50.98 ± 0.67 and IL-8 treated cells mean = 17.62 ± 0.06, 
P<0.05) (Fig. 1A). Moreover, the observed decrease in membrane AAT corresponded 
with a reduction in CD16b expression (control untreated mean fluorescence = 38.75 ± 
0.11 and IL-8 treated cells mean = 19.22 ± 0.05, P<0.05) (Fig. 1B). Furthermore, we have 
previously shown that release of AAT:CD16b complex from the cell membrane in 
response to sIC involves surface sheddase activity including ADAM-17 (25). We 
therefore investigated whether ADAM-17 activity was required for concomitant release 
of AAT with CD16b in response to TNF-alpha. This was confirmed when cells were 
primed with TNF-alpha (10ng/2x10
7
 cells) and the extracellular supernatants analysed by 
Western blot for the presence of released CD16b and AAT (Fig. 1C). TNF-alpha induced 
release of CD16b and AAT at 5 and 10 min post exposure, an effect inhibited by 
inclusion of the  specific ADAM-17 inhibitor, TAPI-1 (10 M) (30).  TAPI-1 prevented 
release of AAT and CD16b in response to TNF-alpha and significantly reduced the 
extracellular detectable level of the two proteins by approximately 80% at the 5 min time 
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point (P<0.05) (Fig. 1D). Collectively, these results demonstrate that neutrophils primed 
by pro-inflammatory mediators including IL-8 and TNF-alpha, rapidly release AAT and 
CD16b from the neutrophil membrane. 
 
3.2 Increased levels of proinflammatory mediators and CD16b:AAT  complex in plasma 
from CF patients. 
Quantification of IL-8 by ELISA revealed significantly elevated levels of IL-8 in 
CF plasma compared to COPD and control subjects (553.8 ± 82.2 versus 249.9 ± 26.2 
and 168.3 ± 51.2 pg/ml plasma respectively, P<0.05) (Fig. 2A). In accordance with 
results obtained for IL-8, significantly elevated levels of TNF-alpha were measured in CF 
plasma compared to COPD and control subjects (10.43 ± 2.12 versus 1.56 ± 0.75 and 
4.16 ± 1.02 pg/ml plasma respectively, P<0.05) (Fig. 2B). Moreover, individuals with CF 
were more likely to have elevated plasma levels of AAT:CD16b compared to COPD and 
control groups
 
 (Fig. 2C). Significantly higher levels of AAT:CD16b protein complex 
were detected in CF patient plasma (6.47 ± 0.65 ng/ml) compared with results from the 
other groups (COPD = 0.73 ± 0.26,  AATD = 0.01 ± 0.005 and control =  0.80 ± 0.24; 
P<0.05) (Fig. 2C). This sandwich ELISA employed a detection antibody to AAT and 
measured negligible levels of AAT:CD16b complex in plasma of AATD individuals. 
Accordingly, this sample cohort served as a negative control and a measure of accuracy 
of the AAT:CD16b ELISA.  
Next, we analyzed the correlation between levels of AAT:CD16b and 
proinflammatory mediators (IL-8 and TNF-alpha) within CF plasma. The combined IL-8 
and TNF-alpha levels in plasma showed a significant positive correlation with the 
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concentration of AAT:CD16b complex (n = 62, r = 0.4223; P = 0.0001; Fig. 3). Taken 
together these results illustrate a novel correlation between increased pro-inflammatory 
mediators and AAT:CD16b complex plasma levels. 
  
3.3 Levels of AAT:CD16b complex in CF patients decrease post antibiotic therapy. 
To determine if levels of AAT:CD16b complex in plasma could reflect the 
inflammatory states of individuals with CF, we carried out analysis of patients plasma 
pre- and post-antibiotic therapy. Patients were treated for an acute microbial exacerbation 
related to Pseudomonas aeruginosa (P. aeruginosa) and/or Staphylococcus aureus (S. 
aureus) bacterial infection predominately. As illustrated in Table 1, an improvement in 
spirometry measurements was observed in most cases following treatment (pretreatment 
FEV1 % predicted mean of 35.20, range 23-48; post-treatment mean 43.60, range 24–
65).  
CF plasma samples before and after intravenous antibiotic therapy were quantified 
for AAT:CD16b complex by ELISA. Of the 10 patient samples analyzed, levels of 
AAT:CD16b decreased after the administration of antibiotic therapy with the exception 
of 2 (Fig. 4A). These latter two patients were deemed nonresponsive to treatment and 
clinical symptoms did not improve with therapy, as measured by a decreased increment 
in FEV1 (Table 1: CF4 & CF6).  
 Proteomic analysis was carried out to evaluate the expression of the AAT:CD16b 
complex on isolated neutrophil membranes pre- and post-therapy.  The 6 patients with CF 
selected for proteomic analysis were representative of the whole group (same degree of 
exacerbation) and controls for this experiment included membrane samples from 6 non-
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CF bronchiectasis (inflammatory control) and 6 healthy control donors. Antibiotic 
treatment modulated expressions of multiple protein spots present on analytical 2-D gel 
images compared to the samples collected without treatment on day 0. In total, ~750 
spots were detected on the 2-D analytical gels by DeCyder software.  When comparing 
the membrane protein spots on the gels from day 0 with that of 14-day post treatment and 
control membranes, 36 spots showed differential expression. Two of these spots were 
down-regulated in CF samples on day 0, while they were increased at least 1.5-fold in 
both the membrane samples from the 14-day-treated CF patients and the samples from 
the control persons (non-CF bronchiectasis and healthy control membranes, P<0.05 by 
ANOVA-1).  Those 2 unknown spots were excised from the gels and identified as AAT 
and CD16b by LC-MS/MS (accession number gi994572 and gi703025, respectively). 
Densitometry of Western blots of CF membranes for AAT and CD16b pre- and post-
antibiotic therapy, confirmed proteomic results (Fig. 4B&C) and indicated significantly 
increased expression of AAT and CD16b (P=0.01 and P=0.05 respectively) on CF 
neutrophil membranes post antibiotic treatment. Of clinical importance, post antibiotic 
treatment, a positive correlation was found between % increase in FEV1 and reduced 
circulating plasma levels of AAT:CD16b (n = 10, r = 0.84, p < 0.005; Fig. 5). 
Collectively these results indicate that treatment of an exacerbation with antibiotic 
therapy in CF results in decreasing levels of plasma AAT:CD16b, with a corresponding 
increase in the level of membrane bound complex and improved FEV1.  
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4. Discussion 
 Pulmonary exacerbations are important contributors to morbidity and are 
associated with lung function decline over 1 year in CF (31). However, a foremost 
obstacle in investigating the processes and functional changes associated with CF 
exacerbations is the lack of a clear diagnostic standard. A circulating biomarker of 
neutrophil priming prior to airway neutrophil migration and activation would serve as a 
specific biomarker for the early detection of CF exacerbations and the subsequent 
response to antibiotic treatment. In this study we have combined well-defined clinical 
groups and demonstrated that plasma levels of neutrophil released AAT:CD16b complex 
correlate with circulating plasma levels of pro-inflammatory mediators. Post antibiotic 
treatment of CF pulmonary exacerbation, we observed an increase in FEV1 and a 
corresponding decrease in plasma protein concentration of AAT:CD16b complex. These 
results indicate that the AAT:CD16b plasma biomarker effectively reflects exacerbations 
of the disease. 
 Research within this area has identified a number of possible biomarkers of CF 
exacerbation. For example, by employing a proteomic approach of induced sputum from 
adult patients with CF, proteolytic degradation and glycosylation of mucins MUC5B and 
MUC5AC (32) or degradation of IgG and alpha-1 antitrypsin, were proposed as 
predictors of CF lung exacerbation (23). By immunometric techniques sputum levels of 
IL-8 have also been shown to significantly alter following treatment of CF exacerbations 
with antibiotic therapy, suggestive of a noninvasive outcome measure to assess response 
to therapy in CF patients (33). However, Downey et al (2007) did not find a reduction in 
sputum IL-8 levels (7), indicating that sputum IL-8 correlates poorly with lung function, 
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thus questioning the suitability of IL-8 as a reliable biomarker of CF exacerbations. 
Therefore as an alternative to using sputum, serum samples from patients with CF have 
also been compared with control sera in order to recognize protein expression profiles 
specific to CF during an exacerbation. Compared to healthy controls, matrix 
metalloproteinase (MMP-1, -8 and -9) and G-CSF serum levels were elevated in adult 
patients with CF and correlated with pulmonary exacerbation and antibiotic treatment 
(19, 20). Serum levels of S100A12 (34), S100A8/A9, CRP and vascular endothelial 
growth factor (35) have also been suggested as serum markers of acute infectious 
exacerbations and to decrease significantly post treatment of an exacerbation. Moreover, 
whilst CF exacerbations were not shown to modulate neutrophil function (36), neutrophil 
derived proteins including myeloperoxidase in peripheral blood appeared to reflect 
inflammatory changes post antibiotic treatment (37). Myeloperoxidase however is a 
component of neutrophil primary / azurophilic granules and peroxidase exocytosis is a 
tightly regulated process. Within the present study, rather than identifying markers of 
neutrophil activation we have focused on a plasma marker of neutrophil pre-activation or 
priming. Priming can be induced by pro-inflammatory stimuli which are increased in an 
in vivo state of CF exacerbation and which prepare the neutrophil for a state of readiness 
preceding complete activation. The fundamental mechanism leading to a primed response 
involves increased levels of cytosolic calcium (38), upregulated tyrosine phosphorylation 
(39) and cytoskeletal rearrangements (40). Pseudomonas alginate (41), TNF-alpha and 
IL-8 have been shown to be important priming agents for  CF neutrophils (42). Recently 
we have shown that AAT is localized to the neutrophil plasma membrane within lipid 
rafts bound to CD16b (FcRIIIb) and is released in complex form (AAT:CD16b) by 
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priming with sIC (25). CD16b is unique in that it is the only Fc receptor linked to the 
plasma membrane by a GPI anchor and the metalloprotease ADAM-17 has been 
implicated in the shedding of CD16b. Within the present study we show that priming of 
neutrophils in vitro with IL-8 and TNF-alpha causes release of CD16b and AAT to the 
extracellular milieu and in vivo, AAT:CD16b complex plasma levels correlate strongly 
with these pro-inflammatory mediators.  
  Although antibiotic responsiveness in the absence of quantitative cultures and 
serotype switching of bacterial species is only suggestive of infective exacerbations, 
within our study combination antibiotic treatment of individuals for an acute exacerbation 
involving P. aeruginosa and/or S. aureus infection resulted in an improvement in FEV1 
in 8 of 10 patients tested. In addition, the changes in plasma AAT:CD16b following 
antibiotic therapy suggested a direct association of plasma levels of AAT:CD16b 
complex with a changing state of airway inflammation and FEV1. Indeed, a soluble form 
of CD16b released from neutrophils and bound to IgG (43) has previously been detected 
in plasma. However, although the soluble CD16b concentration has been shown to 
increase at inflammatory sites (43, 44), a vigorous examination of its use as a plasma 
biomarker of inflammation or in the analysis of antibiotic efficiency has not been 
previously performed. Moreover, the minimum level of soluble CD16b detected by use of 
a monoclonal antibody in normal serum was 7.3nmol/L (43). In contrast, the lowest 
detectable level of plasma AAT:CD16b was 0.006nmol/L. These results suggest 
increased sensitivity of the dual ELISA for detection of the complex biomarker compared 
to CD16b on its own, possibly due to masking of antibody binding sites within the 
protein complex. The present study is however not without limitations. For example 
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correlates of disease states between healthy controls, COPD, AATD and CF individuals 
are not directly comparable since only patients with CF were in exacerbation and only a 
proportion of these patients had before and after samples of plasma analysed. Moreover, 
data indicate that a fraction of the patients with CF would be indistinguishable from the 
other groups when plasma AAT:CD16b complex is used as a sole marker of 
exacerbation. However, in support of the use of AAT:CD16b as an indicator of response, 
proteomic and Western blot analysis of patient neutrophil plasma membranes pre- and 
post-antibiotic treatment revealed increased membrane bound expression of both AAT 
and CD16b post treatment. Moreover, in this study we have developed a novel 
microplate-based protein binding assay employing the use of two antibodies raised 
against AAT and CD16b which allows for rapid screening of multiple serum samples for 
AAT:CD16b interactions. This method measures a precise protein-protein interaction, 
utilizes relatively small amounts of patient sample, is free of protein modification and 
does not require specialized instrumentation.  Thus the clinical benefit of introducing the 
described AAT:CD16b protein binding assay as an effective tool for evaluating 
pulmonary exacerbations is apparent. Conversely however, the cost-effectiveness in 
terms of health quality gained versus cost of implementation requires further evaluation. 
In conclusion, primed neutrophils have been found in peripheral blood during an 
exacerbation of CF, an observation now supported by our study and the identification of 
circulating levels of AAT:CD16b. Upon treatment of an exacerbation plasma levels of 
AAT:CD16b complex decrease significantly, correlating with an improvement in FEV1.  
These observations illustrate that the expression of neutrophil priming-associated 
biomarkers in peripheral blood can be used as read out for the inflammatory process in 
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CF. The AAT:CD16b biomarker may be of benefit to clinical trials determining if drugs-
in-process are effective against inflammation and may also become an extremely useful 
addition to the clinical diagnosis of exacerbations and management of CF. 
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Fig. 1. Pro-inflammatory mediators cause release of AAT and CD16b from the 
neutrophil membrane.     
FACS analysis showing membrane expression of (A), AAT or (B), CD16b on 
membranes of un-stimulated control neutrophils (con) or in response to IL-8 (10 ng/2x10
7
 
cells). The isotype control antibody is illustrated in black (filled). Experiments presented 
were performed in triplicate on three consecutive days. C: Representative immuno-blots 
(one of 3 separate experiments) showing time course of TNF-alpha (10 ng/2x10
7
 cells) 
induced extracellular release of AAT and CD16b from neutrophils with or without TAPI-
1 (10M).   Experiments employed rabbit and goat polyclonal antibody against AAT and 
CD16b respectively. D; Quantification of AAT and CD16b release from neutrophils 
treated with TNF-alpha in the presence or absence of TAPI-1. TAPI-1 significantly 
reduced release of AAT and CD16b (*P<0.05 compared to respective untreated sample). 
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Fig. 2. Protein levels of inflammatory molecules and AAT:CD16b complex in 
plasma from COPD, AATD, CF and healthy controls.  
ELISA analyses of IL-8 (pg/ml) (A), TNF-alpha (pg/ml) (B) or AAT:CD16b complex 
(ng/ml) (C) in plasma from healthy (control; n=14), COPD (n=10), AATD (n=10) and 
CF (n=38) individuals. Statistical significance was analysed by ANOVA, *P<0.05. 
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Fig. 3. Positive correlation between AAT:CD16b protein complex and 
proinflammatory mediators in plasma. 
The correlation between IL-8 (○) and TNF-alpha (●) and plasma AAT:CD16b protein 
complex levels was deemed significant when = 0.05 (Pearson r = 0.42, P<0.0001, R2 = 
0.17).   
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Fig. 4. Levels of AAT:CD16b complex decrease in plasma samples post antibiotic 
therapy. 
 A; ELISA quantification of AAT:CD16b complex (ng/ml) plasma levels before (Pre) 
and 14 days after (Post) antibiotic treatment of patients with CF (n=10). Two 
nonresponsive patients had higher levels of AAT:CD16b complex (dashed line)  B&C; 
Membrane expression of CD16b (B) or AAT (C) on CF neutrophils before (Pre) and after 
(Post) antibiotic therapy. The data presented were calculated using constants obtained of 
Western blot densitometry values. Each measurement is the mean ± S.E (*P<0.05). 
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Fig. 5. Positive correlation between reduced plasma levels of AAT:CD16b protein 
complex and improved FEV1 post antibiotic treatment. 
Correlation between FEV1 (% increase) after two weeks antibiotic treatment of 
individuals with CF (n=10) and changes in plasma levels of AAT:CD16b (ng/ml plasma). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
Supplemental Materials and Methods. 
Proteomic analysis of neutrophil plasma membranes. 
Neutrophil membrane proteins (25 μg) were minimally labelled with 400 pmol Cy2 (CF 
patients when stable, CF patients during an exacerbation, non-CF bronchiectasis and 
healthy control membranes: internal control), Cy3 (CF patients when stable or CF 
patients during an exacerbation) and Cy5 (healthy control or non-CF bronchiectasis) 
according to manufacturer’s instructions (GE Healthcare, Buckinghamshire, UK).  Six 
biological repeats of each comparison were used with reverse labelling on three repeats. 
IEF was performed using immobilised pH gradient (IPG) strips (pH 3-10, 13cm; GE 
Healthcare) and run for a total of 40k V/h at 22
o
C. Prior to electrophoresis in the second 
dimension, IPG strips
 
were equilibrated twice in 10 ml equilibration buffer [30 %
 
(v/v) 
glycerol, 2 % (w/v) SDS, 6 M urea, 50 mM Tris/HCl, pH
 
6.8]. The first equilibration was 
in 10 ml equilibration
 
buffer containing 2 % (w/v) DTT and the second contained 2.5
 
% 
(w/v) iodoacetamide.  After second dimension SDS-PAGE (10% w/v) gels were scanned 
using the Typhoon 9400 variable mode imager (GE Healthcare) with image analysis 
performed using the DeCyder
TM
 Software version 6.5 (GE Healthcare). Statistical 
analysis and quantification of protein abundance was as previously described using the 
biological variation analysis module (BVA) of DeCyder
TM
 (32). Protein identification by 
LC-MS/MS was performed on an Ultimate 3000 nanoLC system (Dionex), interfaced to 
an LTQ Orbitrap XL (Thermo Fisher Scientific) as previously described (30). Database 
searches were performed using TurboSEQUEST software (Bioworks Browser version 
3.3.1) (Thermo Fisher Scientific). The following filters were applied: for charge state 1, 
XCorr>1.5; for charge state 2, XCorr>2.0; for charge state 3, XCorr>2.5.  
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SDS-PAGE and Western blot analyses.  
Samples were subjected to SDS-PAGE under denaturing conditions in 12% NuPAGE® 
gels (Invitrogen™, Carlsbad, CA, USA) following the manufacturer’s instructions. After 
electrophoresis gels were transferred onto 0.2 μm nitrocellulose or PVDF membrane 
(Sigma-Aldrich, St. Louis, MO, USA) by Western blotting using a semi dry blotter for 1 
h at 100mA. Membranes were blocked for 1 h in 3% dry milk (w/v) and 1% bovine 
serum albumin (BSA) in PBS containing 0.25% (v/v) Tween 20 (PBST). Blots were 
incubated with 1.0 μg/ml polyclonal rabbit anti-AAT specific antibody (Abcam, UK) or 
polyclonal goat anti-CD16b specific antibody (R&D Systems, UK).  The secondary 
antibodies were HRP-linked anti-rabbit,   or –goat  IgG (Cell Signalling Technology, 
Danvers, MA, USA). Immuno-reactive protein bands were visualized employing 
SuperSignal® West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) after 
exposure to Kodak® X-Omat LS Film.   
 
Flow cytometry 
Cells remained untreated or treated with IL-8 (10ng/2x10
7
 cells) for 10 min at 37
o
C. 
Neutrophils were fixed (4 % (w/v) paraformaldehyde) and blocked (2% (w/v) BSA) for 
1h and incubated with FITC labeled goat polyclonal anti-AAT (1g/106 cells) (Abcam, 
UK) or mouse anti-CD16b (Santa Cruz) followed by FITC labeled bovine anti-mouse 
secondary antibody (Santa Cruz). Control samples were exposed to relevant non-specific 
isotype control IgG or secondary labeled antibody alone and fluorescence counted by 
flow cytometry. A total of 10,000 events were collected. The data were analyzed using 
BD FACSDiva software (Franklin Lakes, NJ). 
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